Abstract
Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was learned about PARP inhibitor therapy from the TAPUR basket trial.
